4523 N Stock Overview
Engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Eisai Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥888.98 |
| 52 Week High | JP¥1,064.45 |
| 52 Week Low | JP¥888.98 |
| Beta | -0.021 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -38.75% |
| 5 Year Change | n/a |
| Change since IPO | -36.25% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4523 N | MX Pharmaceuticals | MX Market | |
|---|---|---|---|
| 7D | 0% | -0.5% | -0.7% |
| 1Y | n/a | -14.7% | 2.2% |
Return vs Industry: Insufficient data to determine how 4523 N performed against the MX Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 4523 N performed against the MX Market.
Price Volatility
| 4523 N volatility | |
|---|---|
| 4523 N Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in MX Market | 6.1% |
| 10% least volatile stocks in MX Market | 2.2% |
Stable Share Price: 4523 N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 4523 N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1941 | 11,076 | Haruo Naito | www.eisai.co.jp |
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2.
Eisai Co., Ltd. Fundamentals Summary
| 4523 N fundamental statistics | |
|---|---|
| Market cap | Mex$218.90b |
| Earnings (TTM) | Mex$5.18b |
| Revenue (TTM) | Mex$85.55b |
41.4x
P/E Ratio2.5x
P/S RatioIs 4523 N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4523 N income statement (TTM) | |
|---|---|
| Revenue | JP¥749.46b |
| Cost of Revenue | JP¥157.73b |
| Gross Profit | JP¥591.73b |
| Other Expenses | JP¥546.31b |
| Earnings | JP¥45.42b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 158.37 |
| Gross Margin | 78.95% |
| Net Profit Margin | 6.06% |
| Debt/Equity Ratio | 19.7% |
How did 4523 N perform over the long term?
See historical performance and comparisonDividends
2.4%
Current Dividend Yield101%
Payout RatioDoes 4523 N pay a reliable dividends?
See 4523 N dividend history and benchmarks| Eisai dividend dates | |
|---|---|
| Ex Dividend Date | Mar 28 2024 |
| Dividend Pay Date | Jul 01 2024 |
| Days until Ex dividend | 50 days |
| Days until Dividend pay date | 45 days |
Does 4523 N pay a reliable dividends?
See 4523 N dividend history and benchmarks